All filters
Slidesets
Management of hepatitis C therapy failures - virological perspective- Francesca Ceccherini– Silberstein, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Selection of fitness-associated substitutions in patients failing NS5A inhibitors based therapy : analysis of HCV full-length genome deep sequencing by means of shotgun metagenomics- Slim Fourati
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Evaluation of pre-treatment risk factors associated with failure in HCVinfected patients naive to direct acting antivirals: particular focus on natural resistance- Silvia Barbaliscia
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Acute hepatitis A to E, diagnosis and management - Thomas Berg, MD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
B/F/TAF in treatment-naïve HIV-1 and HIV-1 RNA suppressed switch patients- Kirsten White, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Clinical development of ABX464, drug candidate for HIV functional cure- Jean-Marc Steens, MD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Reduced drug regimens- Andrea De Luca, MD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
What is the place of the monoclonal antibodies in the clinic- Julià Blanco, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Meeting
INTEREST 2018
Slidesets
Comparison of 5 online free access expert databases to check drug-drug interactions between antiretroviral drugs and co-prescribed medications from a French cohort of HIV-infected outpatients - Le
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Integrating science, logistics and cost in approval of hierarchical testing strategies for NASH - The payer's perspective- Robert LoNigro, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Pathways and priorities for biomarker assessment- Peter Stein, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Repeatability, reproducibility and analytic standards for biomarker development- Abbas Bandukwala
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Linking “intended use” to evidence needed for bringing a biomarker to market- John Sninsky, PhD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Reporting standards: STARD & TRIPOD- Patrick Bossuyt, PhD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Quality standards for imaging studies- Claude Sirlin, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Case definitions for use as reference standards- Mohammed Siddiqui, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Defining the reference standard for biomarker development - Histology versus clinical outcomes- Kathleen Donohue, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
A Context of Use Framework for Bioanalytical Validation of the CK18 Apoptosis Biomarker for NASH Drug Development- Sumit Kar
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Serum markers of collagen formation are associated with the severity of Liver fibrosis and Non-Alcoholic Steatohepatitis (NASH) histological features and to impaired renal function (IRF) in a NAFLD cohort- Samuel Daniels
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
What is needed to link device approval to clinical application approval?- David Litwack, PhD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Algorithm to identify non-alcoholic steatohepatitis (NASH) patients with a NAS≥4 and F≥2: algorithm derived in an American screening cohort and validation in a British non-alcoholic fatty liver disease (NAFLD) cohort- Celine Fournier
Presented at:
International Workshop on NASH Biomarkers 2018